Market Focus Target neurological disorder therapeutics with external CROs and biotech partners to accelerate clinical development after recent leadership strengthenments in clinical, scientific, and financial roles.

Strategic Expansion Leverage Denmark headquarters as centralized operations while selectively engaging partners in Europe to support a lean headcount and potential access to regional funding or grants.

Partnership Opportunities Capitalize on past collaborations in RNA-based neuroscience and nucleic-acid therapeutics by proposing joint development, CRO services, or platform licensing to extend pipeline progress.

Clinical Acceleration Offer clinical operations and regulatory affairs support, given the appointment of a new Chief Medical Officer, to shorten trial timelines and improve investor confidence for fundraising rounds.

Funding Readiness Position as a partner for pharma and biotech funding events by aligning with their growth trajectory, leveraging the CFO’s role to optimize investor communications and debt/equity financing discussions.